한빛사
>
한빛사논문
한빛사논문
- 조회126
Biomater. Res., November 3, 2025 | https://doi.org/10.34133/bmr.0287
Intranasal Nanoliposomes Delivering Interferon Lambda with Enhanced Mucosal Retention as an Antiviral
Seungju Yang 1,#, Jeongwon Yun 1,#, Jae Hyuk Kwon 2,#, Ji Eun Oh 2,*, Ho Min Kim 1,3*, and Hyun Jung Chung 1,*
1Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea
2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea
3AI Co-Research & Education for Innovative Drug (AI-CRED) Institute, Daejeon, 34141, Republic of Korea
2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea
3AI Co-Research & Education for Innovative Drug (AI-CRED) Institute, Daejeon, 34141, Republic of Korea
#These authors contributed equally
*Corresponding authors: correspondence to Ji Eun Oh, Ho Min Kim or Hyun Jung Chung
Abstract
Respiratory virus infections continue to pose a significant global health challenge, requiring effective prophylactic and therapeutic strategies. Type III interferon (IFN-λ) has shown promise as an antiviral agent that strongly inhibits viral replication while minimizing systemic inflammation. Intranasal administration of IFN-λ allows easy access to the respiratory mucosa, enhancing localized antiviral responses. However, clinical application of IFN-λ is hindered by rapid mucociliary clearance, limited mucosal adhesion, and susceptibility to proteolytic degradation. Here, we develop nanoliposomes that can deliver IFN-λ through an intranasal route (NLp@IFN-λ), and act as an effective antiviral. We demonstrate that the nanoliposomes enable efficient penetration of IFN-λ in a mucus-mimicking model while allowing controlled release of the protein in vitro. Treatment of NLp@IFN-λ could effectively upregulate interferon-stimulated genes in A549 cells, without inducing cytotoxicity. Finally, in vivo delivery of NLp@IFN-λ through a nasal route demonstrates prolonged retention and reduces viral load in nasal tissues in an infection model with influenza virus. This study demonstrates the potential of NLp@IFN-λ as an effective nasal delivery platform for prophylaxis of respiratory virus infections.
논문정보
- Research article
- 2025년 11월 (BRIC 등록일 2025-11-06)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
